A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma (Q34501052)

2 August 2017

title

A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma (English)

1 reference

2 August 2017

9

Blandine Boisselier

0 references

Marc Sanson

11

object named as

Marc Sanson

1 reference

2 August 2017

Aurélie Catteau

1

1 reference

2 August 2017

Hélène Girardi

2

1 reference

2 August 2017

Florence Monville

3

1 reference

2 August 2017

Cécile Poggionovo

4

1 reference

2 August 2017

Sabrina Carpentier

5

1 reference

2 August 2017

Véronique Frayssinet

6

1 reference

2 August 2017

Jesse Voss

7

1 reference

2 August 2017

Robert Jenkins

8

1 reference

2 August 2017

Karima Mokhtari

10

1 reference

2 August 2017

Hélène Peyro-Saint-Paul

12

1 reference

2 August 2017

Caterina Giannini

13

1 reference

2 August 2017

publication date

2 June 2014

1 reference

Acta Neuropathologica Communications

2 August 2017

published in

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

page(s)

58

1 reference

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Predictive biomarkers in adult gliomas: the present and the future

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Molecular neuro-oncology in clinical practice: a new horizon

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Interlaboratory comparison of IDH mutation detection.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH1 and IDH2 mutations in gliomas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

The Catalogue of Somatic Mutations in Cancer (COSMIC)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

The 2007 WHO classification of tumours of the central nervous system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

7 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

BRAF alterations are frequent in cerebellar low-grade astrocytomas with diffuse growth pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

COLD PCR HRM: a highly sensitive detection method for IDH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

PCR- and restriction endonuclease-based detection of IDH1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Expanding the spectrum of IDH1 mutations in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4229941

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee

27 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F2051-5960-2-58

21 January 2018

Identifiers

DOI

10.1186/2051-5960-2-58

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference